Deals channel feed

Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

4 years ago
R&D

In­side the deal: Sanofi flipped from sell-off to merg­er in lead up to $3.2B Trans­late buy­out

4 years ago

Vec­tura board says it will unan­i­mous­ly back a Philip Mor­ris takeover

4 years ago

Out to re­vamp plant-based drug man­u­fac­tur­ing, An­theia locks in part­ner­ship with syn­thet­ic bi­ol­o­gy gi­ant Gink­go

4 years ago
Manufacturing

The Car­lyle Group ax­es auc­tion by call­ing its $1.3B bid for Vec­tura 'fi­nal' — now the ball is in Philip Mor­ris' court

4 years ago

As Ab­b­Vie and Soli­ton shake hands on a $550M merg­er, the FTC says 'not so fast'

4 years ago

A decades-old glau­co­ma drug tossed aside by Pfiz­er gets a new life at a small biotech

4 years ago
People

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

4 years ago
China

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

4 years ago
Pharma

Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

4 years ago
Cell/Gene Tx
Manufacturing

Robert Baze­more inks one last deal for Epizyme — adding Chi­na to Tazverik's glob­al blue­print — be­fore head­ing out from CEO of­fice

4 years ago
China

Philip Mor­ris bags an­oth­er biotech as bid­ding war with Car­lyle over Vec­tura deal heats up

4 years ago

Drug pric­ing dis­rup­tor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

4 years ago
Financing

Chi­nese start­up with Mer­ck vet at the helm ac­quires rights to Oys­ter Point's eye dis­ease nasal spray

4 years ago
China

mGx M&A? Mod­er­na ex­ecs are lever­ag­ing their Covid cash on gene edit­ing, gene ther­a­py deals

4 years ago
Bioregnum

With an as­sist from As­traZeneca, the sal­vage crew at Sier­ra bets an­oth­er $216M they can res­ur­rect an old Gilead JAK drug

4 years ago

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ther­a­pies

4 years ago

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO con­ga line

4 years ago

Soft­Bank claims $5B stake in Roche amid grand plans to in­vest in biotech — re­ports

4 years ago

Saman­tha Du's Zai Lab inks sur­pris­ing re­search col­lab with Schrödinger for DNA dam­age drug

4 years ago
R&D
China

Af­ter strug­gling with its sole drug for years, Mar­i­nus rides pos­i­tive da­ta to a com­mer­cial­iza­tion deal in Eu­rope

4 years ago
FDA+

Sanofi buys mR­NA play­er Trans­late Bio for $3.2B. And the price fits a pop­u­lar range for biotech M&A

4 years ago

Ab­cam brings a long­time col­lab­o­ra­tor in house as part of $340M buy­out pact

4 years ago
Outsourcing

Mod­er­na takes on a low-risk pact with CAR-T play­er Au­to­lus for mR­NA-based can­cer drugs

4 years ago
First page Previous page 72737475767778 Next page Last page
A service from the Financial Times